FY22 Invention Disclosures
FY22 U.S. Patents Issued
FY22 Licensing Revenue
FY22 New IP Based Startups
This is WashU Innovation
The Office of Technology Management assists WashU faculty in the transfer of technology from the lab to the global marketplace.
Explore our innovation community
A research powerhouse becomes an innovation incubator
“We believe in the idea that research can improve health outcomes, decrease health-care costs and improve the regional economy.” — David H. Perlmutter, MD, executive vice chancellor for medical affairs and the George and Carol Bauer Dean of the School of Medicine
A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is on the path to becoming available in the U.S., Europe and Japan.
The world’s first nasal vaccine for COVID-19 was approved Tuesday, Sept. 6, in India for emergency use. The vaccine, called iNCOVACC, is based on technology licensed from Washington University in St. Louis and developed in collaboration with Bharat Biotech International Limited in India.
The search for effective treatments has been hampered because these highly structured cells cannot be cultured outside of the body, and because immortalized cell lines are not true to their structure. New research from Washington University’s McKelvey School of Engineering and the School of Medicine aims to overcome this critical barrier.
Resources for Students & Alumni
The Skandalaris Center for Interdisciplinary Innovation and Entrepreneurship serves as the primary resource for students and alumni.